Pyng Medical Corp. Announces Exclusive Agreement With Tri-anim Health Services Inc. for US Hospital Distribution

VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 19, 2009) - Pyng Medical Corp. (the “Company”) (TSX VENTURE: PYT) announces the signing of an exclusive US hospital distribution agreement with Tri-anim Health Services of Sylmar, CA, USA.

“We are excited about the exclusive partnership with Pyng Medical and their unique product line. This is an excellent opportunity, which supports our goal of providing unique products that provide better patient outcomes to clinicians and patients. The T-POD® and FAST1® will provide improved clinical solutions for emergency medical care in the hospital,” said Tom Sampson, Area Vice President for Tri-anim.

“This new partnership is the culmination of a relationship between Tri-anim and Pyng Medical. Tri-anim’s commitment to excellence in customer service with their 100 person direct sales team makes them an invaluable partner serving the US hospital distribution channel,” said Nadine Gaston, Vice President of Sales for Pyng. “Tri-anim’s exclusive agreement to distribute the FAST1® for Intraosseous Infusion and T-POD® for Pelvic Stabilization is a testament to the unsurpassed quality of Pyng Medical products and our commitment to fill a critical gap in emergency resuscitative care. We are proud to be associated with Tri-anim and look forward to working with them,” continued Ms. Gaston.

About Tri-anim Health Services

Tri-anim is a national distributor of healthcare products that offers both innovative products and those that meet everyday needs. For more than 30 years, they have introduced leading-edge technologies that have met the needs and exceeded the expectations of hospitals, surgery centers, long-term care facilities, nursing homes and other clinical settings throughout the healthcare continuum.

Tri-anim is an industry leader providing e-commerce solutions enabling customers a faster and more efficient procurement method for purchasing medical products. The e-Quick® System, a proprietary patent pending technology, allows customers to place a five-line order in less than 45 seconds. For more information go to www.tri-anim.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools including the T-POD® Pelvic Stabilizer and MAT® Tourniquet. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like “expects”, “anticipates”, “plans”, “intends”, “projects”, “indicates”, and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.